Phase 2 N=33 Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures
Malignant Neoplasm
Primary: Total Dose of Propofol Administered to Each Patient — 2.94; 3.22 mg/kg — p=0.036
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Recurrent Small Cell Lung Carcinoma
Primary: 18 Week Progression-free Survival Rate — 35; 72 percentage of participants
Phase 2 N=11 N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder
Primary: OCD Severity at 12 Weeks — 21.4; 21.3 points on a scale
Phase 2 N=3 WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia · Myelodysplastic Syndrome With Isolated Del(5q) · Myelodysplastic/Myeloproliferative Neoplasm
Primary: Complete Response Rate (CR or CRi) Per the National Comprehensive Cancer Network (NCCN) Guidelines or According to Specific Criteria From Expert Panels — 0 percentage of…
Phase 2 N=25 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Change From Baseline in Maximum Standard Uptake Values (SUVmax) — -0.98; 0.09; 0.10; -1.90 ratio
Phase 2 N=20 Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia (HHT)
Primary: Measurement of Epistaxis in Patients With HHT as Measured by the HHT Foundation Epistaxis Severity Score, Hematocrit, Hemoglobin and Serum Ferritin Levels.
Phase 2 N=65 Qsymia as an Adjunct to Surgical Therapy in the Superobese
Obesity · Metabolic Surgery · Weight Loss
Primary: Proportion of Patients Who do Not Meet the Criteria to Move Forward With Roux en Y Gastric Bypass (RYGB) — 8; 19 Participants
Phase 2 N=31 A Novel Biologic Therapy for Perennial Allergic Rhinitis
Allergic Rhinitis
Primary: Daily Combined Score (DCS) — -4.41; -1.61 DCS (daily combined score)
Phase 2 N=120 The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery
Peanut Allergy
Primary: Passing the Week 117 DBPCFC to Peanut — 21; 19; 1 participants
Phase 2 N=39 Oxytocin as Adjunctive Treatment of Schizophrenia
Schizophrenia
Primary: Eye Tracking: Fixation Count — 6.78; 9.19; 9.88; 7.94 Number of face fixations
Phase 2 N=37 Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures
Opioid-induced Constipation
Primary: Percentage of Participants With Laxation Response Within 2 Hours of the First Dose — 33.33; 0 percentage of participants — p=0.0213
Phase 2 N=171 Males, Antioxidants, and Infertility Trial
Male Infertility
Primary: Live Birth Rate — 15.3; 22.1 percentage of live births
Phase 2 N=120 Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
Primary Myelofibrosis (MF) · Post-Polycythemia Vera (PV) MF · Post-Essential Thrombocythemia (ET) MF
Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24 — 38 Participants — p=0.0007
Phase 2 N=102 Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Keratoconjunctivitis Sicca
Primary: Change From Baseline in Corneal Total Fluorescein Staining Score at for the Study Eye at Week 4 — -1.3; -1.7; -1.3 units on a scale — p=0.6199
Phase 2 N=86 Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
HIV-1 · Central Nervous System
Primary: Percentage of Participants With at Least One Central Nervous System (CNS) Toxicity of at Least Grade 2 Intensity at Week 12 — 41.9; 37.2 Percentage of participants…